Table 2.

All-cause mortality HR of prior melanoma diagnosis β-blocker use obtained from an ITT analysis using Cox proportional hazards models

Modelsa	Melanoma as a cause of death (N = 3,428)				All-cause mortality (N = 4,179)
	Number of deathsb	β-Blocker HRb	95% CI	P	Number of deathsb	β-Blocker HRa	95% CI	P
All subjects	416				1,167
Exposure 90 d prior to diagnosis	46	0.87	0.64–1.20	0.408	143	0.81	0.67–0.97	0.020
Exposure >90 d prior to diagnosis	11	0.36	0.20–0.66	0.001	62	0.78	0.60–1.00	0.052
Stage I and II melanoma
Exposure 90 d prior to diagnosis	29	0.93	0.62–1.40	0.734	92	0.83	0.67–1.05	0.120
Exposure >90 d prior to diagnosis	4	0.31	0.12–0.85	0.022	23	0.69	0.46–1.06	0.088
Stage III and IV melanoma
Exposure 90 d prior to diagnosis	14	1.26	0.71–2.23	0.421	24	1.20	0.78–1.86	0.405
Exposure >90 d prior to diagnosis	5	0.87	0.34–2.23	0.765	10	0.93	0.48–1.80	0.843

^aβ-Blocker HR is adjusted for age and comorbidity index score, and the referent group is no β-blocker exposure prior to melanoma diagnosis.

^bCounts in stages I to IV do not total to the all subjects count because of missing or unspecified stage data.